ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2210

Redefining Dermatomyositis: Description of New Diagnostic Criteria That Differentiate Pure Dermatomyositis from Overlap Myositis with Dermatomyositis Features

Marie-Pier Payette1, Yves Troyanov1, Ira N. Targoff2, Jean-Pierre Raynauld1, Suzanne Chartier3, Jean-Richard Goulet1, Josiane Bourré-Tessier1, Eric Rich1, Tamara Grodzicky1, Marvin J. Fritzler4, France Joyal5, Martial Koenig5 and Jean-Luc Senécal1, 1Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 2Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Division of Dermatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 4Mitogen Advanced Diagnostics Laboratory, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, 5Department of Medicine, Division of Internal Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: dermatomyositis and myositis

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Dermatomyositis (DM) is a major form of autoimmune myositis (AIM). The characteristic DM rash (Gottron’s papules, heliotrope rash) and perifascicular atrophy (PFA) at muscle biopsy are regarded as diagnostic. However, new concepts are challenging the definition of DM. A modified Bohan and Peter clinical classification (mcBP) of AIM was proposed. In the mcBP, overlap features in presence of myositis allow a diagnosis of overlap myositis (OM), irrespective of the presence or absence of the DM rash or PFA. Therefore, our objective was to further differentiate DM from OM.

Methods:

Using the mcBP, we performed a longitudinal study of 100 AIM patients, including 44 patients with a DM phenotype, defined as DM rash, and/or DM-type calcinosis and/or PFA at biopsy. Overlap features, DM rash course, adermatopathic DM (aDM), cancer and survival were evaluated, as well as DM-specific and overlap autoantibodies by protein A immunoprecipitation.

Results:

Two subsets were identified in patients with a DM phenotype: pure DM (n=24) and OM with DM features, or OMDM (n=20). In pure DM, the rash of DM was the first disease manifestation, was always present at the time of myositis diagnosis, and was chronic and associated with a high cutaneous score. Concurrent heliotrope rash and Gottron papules (PPV 91%), as well as the V-sign and/or shawl sign (PPV 100%), were diagnostic of pure DM. Anti-Mi-2, anti-MJ and anti-p155 autoantibodies were restricted to pure DM (PPV 100%) and present in 50% of patients. 21% of patients had cancer. Fifteen-year survival was high (92%).

In contrast, in OMDM the first manifestation was proximal muscle weakness or other skeletal muscle-related complaints. The DM rash appeared at diagnosis or followup and was associated with a low cutaneous score. aDM, absent in pure DM, predicted OMDM (PPV 100%). Autoantibodies, found in 70% of patients, included anti-Jo-1, anti-PL-7, anti-PM-Scl, anti-U1RNP and anti-U5-RNP.  OMDM was not associated with cancer but 15-year survival was only 65%.  

PFA occurred as commonly in OMDM (n=6/20 patients, 30%) as in pure DM (n=4/24, 17%). These 6 OMDM patients had aDM at the time of myositis diagnosis. Only one of them developed a DM rash at follow-up, emphasizing the lack of specificity of PFA for pure DM.

Conclusion:

Using the mcBP allowed identification of OMDM, a new clinical subset of OM. Furthermore, identification of OMDM allowed in turn recognition of pure DM as a new entity, distinct from OMDM or from OM without DM features. However, the absolute specificity of a DM rash and PFA for the diagnosis of pure DM was lost.


Disclosure:

M. P. Payette,
None;

Y. Troyanov,
None;

I. N. Targoff,
None;

J. P. Raynauld,
None;

S. Chartier,
None;

J. R. Goulet,
None;

J. Bourré-Tessier,
None;

E. Rich,
None;

T. Grodzicky,
None;

M. J. Fritzler,

INOVA Diagnostics Inc.,

9;

F. Joyal,
None;

M. Koenig,
None;

J. L. Senécal,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/redefining-dermatomyositis-description-of-new-diagnostic-criteria-that-differentiate-pure-dermatomyositis-from-overlap-myositis-with-dermatomyositis-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology